查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1772267

美国心率管理设备市场规模、份额、趋势分析报告：2025-2033年产品细分预测

U.S. Cardiac Rhythm Management Devices Market Size, Share & Trends Analysis Report By Product (Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT)), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

预计 2024 年美国心率管理设备市场价值将达到 68 亿美元，预计 2025 年至 2033 年的复合年增长率为 6.6%。

由于临床需求不断增长、设备技术不断发展以及远距远端医疗日益融合，美国心率管理设备市场正在不断发展变化。各公司正在根据这些变化调整其产品策略，重点关注小型化、连接性和持续监测，以支持急性和长期患者管理。

2024年5月，Defibtec在美国扩展了其Lifeline VIEW和ECG心臟去颤器产品线，推出了一款具有英语和西班牙语切换功能的双语AED型号。这些更新旨在提高突发心臟紧急情况下不同急救人员的可及性和易用性。

在美国，心律不整和心臟衰竭的负担日益加重，加速了心率管理设备的需求。人口老化加上高血压、肥胖症和糖尿病等合併症的增加，对可靠的长期心臟介入措施的需求持续增加。心律调节器、心臟去颤器和再同步系统等设备正成为管理慢性心臟疾病和预防心臟性猝死的重要工具。 2024 年 9 月，加州大学旧金山分校的研究人员在《美国心臟病学会杂誌》上发表了一项研究，估计心房颤动影响 1,055 万美国成年人。该分析基于 2005 年至 2019 年加州超过 2900 万份医院记录，显示目前的盛行率几乎是先前估计值的三倍，并且正在影响更年轻、更多样化的人群。

心臟衰竭是一种慢性、进行性疾病，患者心臟无法有效泵血，常导致住院治疗、生活品质下降和高死亡率。心臟衰竭给医疗保健系统带来沉重的负担，尤其是在人口老化和糖尿病、高血压等併发症日益增多的情况下。以设备为基础的介入措施，例如心率管理设备和导线管理系统，对于心臟衰竭患者的早期诊断、稳定和长期照护越来越重要。根据美国心臟衰竭协会 2025 年 1 月的数据，美国约有 670 万 20 岁及以上的成年人心臟衰竭，预计这一数字将在 2030 年达到 870 万，2040 年达到 1030 万，2050 年达到 1140 万。

设备工程的进步正在再形成市场，尤其是无导线和无线技术的出现。无导线起搏器减少了与传统系统相关的併发症并简化了嵌入型，而无线平台则改善了通讯和同步。这些增强功能提高了安全性、易用性和长期可靠性，使其在医院和门诊环境中都越来越有吸引力。 2025 年 4 月，Medtronic的Omnia Secure 获得了 FDA 批准，这是一款专为植入式去心房颤动定制的微型去心房颤动导线。其紧凑的 4.7 French 尺寸支持精确放置，同时降低了血管和瓣膜併发症的可能性。在 Heart Rhythm 2025 上发表的 LEADR 试验结果报告了植入时去心房颤动完全成功。

远端监控与心臟护理工作流程的整合正在推动医疗服务提供者的广泛采用。嵌入型装置的即时资料传输有助于及早发现心律不整和装置效能问题，从而减少计划外干预并支持主动护理模式。此功能也符合更广泛的数位医疗策略，并符合支付方减少昂贵就诊次数的利益。 2025年3月，MicroPort CRM获得CE标誌核准，并在欧洲推出了其SmartView Connect行动应用。这款安卓应用程式将支援蓝牙的起搏器与诊所连接起来，无需床边监护仪即可对心搏过缓患者进行安全的远端监控。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国心率管理设备市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国心率管理设备市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国心率管理设备市场：产品评估与趋势分析

  • 美国心率管理设备市场：产品仪表板
  • 美国心率管理设备市场：产品差异分析
  • 美国心率管理设备市场（按产品和收益）
  • 起搏器
    • 嵌入型
    • 体外
  • 心臟去颤器
    • 嵌入型心臟去颤器（ICD）
    • 体外心臟去颤器
  • 心臟再同步治疗（CRT）
    • CRT心臟去颤器
    • CRT心律调节器

第五章 竞争态势

  • 主要製造商的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2024
  • 公司简介
    • Medtronic
    • Boston Scientific Corporation
    • Abbott
    • Schiller AG
    • Stryker
    • Koninklijke Philips NV
    • Biotronik
    • Progetti Srl
    • MicroPort Scientific Corporation
Product Code: GVR-4-68040-640-8

Market Size & Trends:

The U.S. cardiac rhythm management devices market size was estimated at USD 6.8 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2033. The U.S. cardiac rhythm management market is advancing through a convergence of growing clinical demand, evolving device technologies, and greater integration of remote care. Companies are aligning product strategies with these shifts, emphasizing miniaturization, connectivity, and continuous monitoring to support both acute and long-term patient management.

In May 2024, Defibtech expanded its Lifeline VIEW and ECG defibrillator lines in the U.S. by launching dual-language AED models with English and Spanish toggle features. These updates aim to improve accessibility and usability for diverse responders during sudden cardiac emergencies.

The increasing burden of arrhythmias and heart failure in the U.S. is accelerating the demand for cardiac rhythm management devices. An aging population combined with a rise in comorbidities such as hypertension, obesity, and diabetes is creating a steady need for reliable long-term cardiac interventions. Devices such as pacemakers, defibrillators, and resynchronization systems are becoming critical tools in managing chronic cardiac conditions and preventing sudden cardiac death. In September 2024, researchers from the University of California, San Francisco published a study in the Journal of the American College of Cardiology estimating that atrial fibrillation affects 10.55 million U.S. adults. The analysis, based on over 29 million hospital records in California from 2005-2019, revealed that current prevalence is nearly triple the earlier estimates and increasingly affects younger, more diverse populations.

Heart failure is a chronic, progressive condition marked by the heart's inability to pump blood effectively, often resulting in hospitalizations, reduced quality of life, and high mortality. It places a growing burden on healthcare systems, especially with aging populations and rising comorbidities such as diabetes and hypertension. Device-based interventions, including cardiac rhythm management and lead management systems, are increasingly essential for early diagnosis, stabilization, and long-term care in heart failure patients. In January 2025, according to the Heart Failure Society of America, around 6.7 million U.S. adults over 20 have heart failure, with prevalence projected to reach 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050.

Advances in device engineering are reshaping the market, particularly with the emergence of leadless and wireless technologies. Leadless pacemakers reduce complications associated with conventional systems and simplify implantation, while wireless platforms improve communication and synchronization. These enhancements offer greater safety, ease of use, and long-term reliability, making them increasingly attractive in both hospital and ambulatory settings. In April 2025, Medtronic gained FDA clearance for the OmniaSecure, a miniaturized defibrillation lead tailored for implantable cardioverter-defibrillator systems. Its compact 4.7 French size supports accurate placement while lowering the chance of vascular or valve complications. Findings from the LEADR trial, shared at Heart Rhythm 2025, reported full defibrillation success at implantation.

The integration of remote monitoring into cardiac care workflows is driving further adoption across healthcare providers. Real-time data transmission from implanted devices enables early detection of arrhythmias and device performance issues, reducing unplanned interventions and supporting proactive care models. This capability also aligns with broader digital health strategies and payer interest in minimizing costly hospital visits. In March 2025, MicroPort CRM launched the SmartView Connect App Mobile in Europe after receiving CE mark approval. The Android app links Bluetooth-enabled pacemakers to clinics, enabling secure remote monitoring without bedside monitors for bradycardia patients.

U.S. Cardiac Rhythm Management Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 - 2033. For this study, Grand View Research has segmented the U.S. cardiac rhythm management devices market report based on product:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Pacemakers
    • Implantable
    • External
  • Defibrillators
    • Implantable Cardioverter Defibrillators (ICD)
    • S-ICD
    • T-ICD
    • External Defibrillator
    • Manual External Defibrillator
    • Automatic External Defibrillator
    • Wearable Cardioverter Defibrillator
  • Cardiac Resynchronization Therapy (CRT)
    • CRT-Defibrillator
    • CRT-Pacemakers

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Volume price analysis (Model 1)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Cardiac Rhythm Management Devices Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of arrhythmias and heart failure
      • 3.2.1.2. Advancements in leadless and wireless cardiac devices
      • 3.2.1.3. Integration of remote monitoring with cardiac care platforms
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk of device-related complications and recalls
      • 3.2.2.2. Stringent regulatory approvals and reimbursement challenges
  • 3.3. U.S. Cardiac Rhythm Management Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Cardiac Rhythm Management Devices Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Cardiac Rhythm Management Devices Market: Product Dashboard
  • 4.2. U.S. Cardiac Rhythm Management Devices Market: Product Movement Analysis
  • 4.3. U.S. Cardiac Rhythm Management Devices Market by Product, Revenue
  • 4.4. Pacemakers
    • 4.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.4.2. Implantable
      • 4.4.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.4.3. External
      • 4.4.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5. Defibrillators
    • 4.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.2. Implantable Cardioverter Defibrillators (ICD)
      • 4.5.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.2.2. S-ICD
        • 4.5.2.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.2.3. T-ICD
        • 4.5.2.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.3. External Defibrillator
      • 4.5.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.3.2. Manual External Defibrillator
        • 4.5.3.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.3.3. Automatic External Defibrillator
        • 4.5.3.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.3.4. Wearable Cardioverter Defibrillator
        • 4.5.3.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.6. Cardiac Resynchronization Therapy (CRT)
    • 4.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.6.2. CRT-Defibrillator
      • 4.6.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.6.3. CRT-Pacemaker
      • 4.6.3.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. List of key distributors and channel partners
    • 5.3.2. Key customers
    • 5.3.3. Key company market share analysis, 2024
  • 5.4. Company Profiles
    • 5.4.1. Medtronic
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Boston Scientific Corporation
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. Abbott
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Schiller AG
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. Stryker
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. Koninklijke Philips N.V.
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Biotronik
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Progetti Srl
      • 5.4.8.1. Company overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. MicroPort Scientific Corporation
      • 5.4.9.1. Company overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. cardiac rhythm management devices market, by product, 2021 - 2033 (USD Million)
  • Table 3 Participant's overview
  • Table 4 Financial performance
  • Table 5 Key companies undergoing expansions
  • Table 6 Key companies undergoing acquisitions
  • Table 7 Key companies undergoing collaborations
  • Table 8 Key companies launching new services
  • Table 9 Key companies undergoing partnerships
  • Table 10 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. cardiac rhythm management devices market segmentation
  • Fig. 7 Market snapshot, 2024
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market driver relevance analysis (current & future impact)
  • Fig. 10 Market restraint relevance analysis (current & future impact)
  • Fig. 11 Swot analysis, by factor (political & legal, economic, and technological)
  • Fig. 12 Porter's five forces analysis
  • Fig. 13 U.S. cardiac rhythm management devices market: Product Outlook Key Takeaways
  • Fig. 14 U.S. cardiac rhythm management devices market: Product Movement Analysis
  • Fig. 15 Pacemakers market, 2021 - 2033 (USD Million)
  • Fig. 16 Implantable pacemakers market, 2021 - 2033 (USD Million)
  • Fig. 17 External pacemakers market, 2021 - 2033 (USD Million)
  • Fig. 18 Defibrillators market, 2021 - 2033 (USD Million)
  • Fig. 19 Implantable cardioverter defibrillators (ICD) market, 2021 - 2033 (USD Million)
  • Fig. 20 S-ICD market, 2021 - 2033 (USD Million)
  • Fig. 21 T-ICD market, 2021 - 2033 (USD Million)
  • Fig. 22 External defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 23 Manual external defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 24 Automatic external defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 25 Wearable cardioverter defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 26 Cardiac resynchronization therapy (CRT) market, 2021 - 2033 (USD Million)
  • Fig. 27 CRT-defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 28 CRT-pacemakers market, 2021 - 2033 (USD Million)
  • Fig. 29 Strategy framework